Rothschild Investment LLC’s Blueprint Medicines BPMC Stock Holding History

Rothschild Investment LLC’s Portfolio BPMC Stock Details BPMC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-130	Closed	-$16.7K	–	3158
2025 Q2	$16.7K	Buy	130 +65	+100%	+$6.75K	﹤0.01%	1063
2025 Q1	$5.75K	Hold	65	–	–	﹤0.01%	1371
2024 Q4	$5.67K	Buy	65 +5	+8%	+$458	﹤0.01%	1301
2024 Q3	$5.55K	Buy	60 +35	+140%	+$3.48K	﹤0.01%	1259
2024 Q2	$2.69K	Buy	25 +20	+400%	+$2K	﹤0.01%	1308
2024 Q1	$474	Buy	+5	New	+$429	﹤0.01%	1377

Other funds holding BPMC

DekaBank Deutsche Girozentrale Frankfurt, Germany $59.2B AUM 26.02% 1-Year Est. Return

VanEck Associates New York $133B AUM 72.99% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

HNB

Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Rothschild Investment LLC's BPMC Position: Q3 2025 in Review

Rothschild Investment LLC sold out of Blueprint Medicines (BPMC) in Q3 2025, closing a stake of 130 shares — an estimated $16.7K sold.

Rothschild Investment LLC first reported a position in BPMC in Q1 2024 and held it in 6 quarters. The position peaked at $16.7K in Q2 2025. 5 funds tracked by Wall St. Rank hold BPMC as of Q3 2025.

Rothschild Investment LLC reported no remaining Blueprint Medicines position as of Q3 2025 after selling out during the quarter.
Rothschild Investment LLC sold 130 Blueprint Medicines shares in Q3 2025, an estimated $16.7K.
Rothschild Investment LLC first reported a position in Blueprint Medicines in Q1 2024 and held it in 6 quarters.
Rothschild Investment LLC's Blueprint Medicines position peaked at $16.7K in Q2 2025.
5 funds tracked by Wall St. Rank held Blueprint Medicines as of Q3 2025.

Based on Rothschild Investment LLC's 13F filing for Q3 2025, filed 7 Nov 2025.